Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15970859 | 0.76 | HDAC8 (0.50) | HDAC8HSD17B10IRAK4 | |
| SCHEMBL24156274 | 0.73 | HDAC8 (0.37) | HDAC8HSD17B10IRAK4SMN1; SMN2 | |
| SCHEMBL447125 | 0.73 | HTR2A (0.39) | HDAC8IRAK4SMN1; SMN2 | |
| SCHEMBL3303776 | 0.73 | HSD17B10 (0.46) | HDAC8HSD17B10IRAK4SMN1; SMN2 | |
| SCHEMBL413086 | 0.72 | ENPP3 (0.39) | HDAC8HSD17B10 | |
| SCHEMBL15970721 | 0.71 | HDAC8 (0.46) | HDAC8HSD17B10IRAK4 | |
| SCHEMBL28359101 | 0.70 | IRAK4 (0.44) | IRAK4 | |
| SCHEMBL7886143 | 0.69 | HDAC8 (0.38) | HDAC8HSD17B10IRAK4SMN1; SMN2 | |
| SCHEMBL23119771 | 0.69 | HSD17B10 (0.39) | HDAC8HSD17B10IRAK4SMN1; SMN2 | |
| SCHEMBL31018253 | 0.67 | ADORA3 (0.32) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655300-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-19 | — | — | US | disclosed |
| WO-2024158929-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3887358-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166076-A | Heterocyclic compounds for the treatment of epilepsy | 大塚制药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020111263-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | SLC6A11, SCN1A, SCN1B | HDAC8 120/4885HSD17B10 198/4885IRAK4 2777/4885 |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | HDAC8 120/4885HSD17B10 198/4885IRAK4 2777/4885 |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, KCNH1 | HDAC8 129/4885HSD17B10 194/4885IRAK4 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.